ArticleDiabetes2017
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.
Article in Diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03658031 (Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review.Journal of diabetes research · 2020Pooled it
- Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis.Bioscience reports · 2019Pooled it
- Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.Diabetes care · 2026Trial
- Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes.Diabetes care · 2025Trial
- Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study.Diabetes & metabolism journal · 2021Trial
- Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy.Diabetologia · 2020Trial
- Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.Diabetes care · 2020Trial
- Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).Trials · 2019Trial
- Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.Diabetes · 2018Trial
- SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy.American heart journal plus : cardiology research and practice · 2026Article
- Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin.Blood advances · 2024Article
- SGLT2 inhibition promotes glomerular repopulation by cells of renin lineage in experimental kidney disease.Acta physiologica (Oxford, England) · 2024Article
- Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases.Frontiers in pharmacology · 2024Article
- Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2023Article
- Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria.Acta pharmaceutica Sinica. B · 2023Article
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Article
- SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review.Journal of clinical medicine · 2022Review
- Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy.Journal of clinical medicine · 2021Review
- Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney.Diabetes spectrum : a publication of the American Diabetes Association · 2021Article
- Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report.Italian journal of pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Renal glucose reabsorption was measured with the stepped hyperglycemic clamp in 15 subjects with type 2 diabetes mellitus (T2DM) and 15 without diabetes after 2 days and after more chronic (14 days) treatment with empagliflozin. Patients with T2DM had significantly greater maximal renal glucose transport (Tm
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.